1.13

1.80% 0.02

After Hours: 1.12 -0.010 -0.88%

Opko Health Inc (OPK)

Overview News Price History Option Chain Financials Why OPK Down? Discussions Forecast

Opko Health Inc stock is traded at $1.13, with a volume of 1.76M. It is up +1.80% in the last 24 hours and down -0.88% over the past month. OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Previous Close:

$1.11

Open:

$1.11

24h Volume:

1.76M

Relative Volume:

0.70

Market Cap:

$853.25M

Revenue:

$581.12M

Net Income/Loss:

$-212.92M

P/E Ratio:

-4.1271

EPS:

-0.2738

Net Cash Flow:

$-174.22M

1W Performance:

-6.61%

1M Performance:

-0.88%

6M Performance:

-15.67%

1Y Performance:

-16.91%

1-Day Range:

$1.11

$1.13

1-Week Range:

$0.9769

$1.1899

52-Week Range:

$0.9769

$1.60

Opko Health Inc Stock (OPK) Company Profile

Name

Opko Health Inc

Sector

Healthcare (1106)

Industry

Diagnostics & Research (52)

Phone

305-575-4181

Address

4400 BISCAYNE BLVD., MIAMI, FL

Employee

2,275

Twitter

Next Earnings Date

2026-04-28

Latest SEC Filings

OPK's Discussions on Twitter

Compare OPK vs TMO, DHR, IDXX, WAT, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OPK Opko Health Inc	1.13	838.15M	581.12M	-212.92M	-174.22M	-0.2738
TMO Thermo Fisher Scientific Inc	466.76	171.91B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	174.63	123.18B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	562.97	44.73B	4.30B	1.06B	1.04B	13.08
WAT Waters Corp	342.75	29.63B	3.17B	642.63M	516.49M	10.77
A Agilent Technologies Inc	117.53	31.70B	7.07B	1.29B	993.00M	4.5355

Opko Health Inc Stock (OPK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-25	Initiated	JP Morgan	Neutral
Oct-31-25	Downgrade	Jefferies	Buy → Hold
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy
Nov-25-19	Initiated	Piper Jaffray	Overweight
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy
Jun-03-16	Initiated	Standpoint Research	Buy
Mar-31-16	Reiterated	Barrington Research	Outperform
Oct-16-15	Initiated	JP Morgan	Overweight
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform
Mar-14-14	Initiated	Oppenheimer	Outperform
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy
May-30-13	Reiterated	Ladenburg Thalmann	Buy
Oct-22-12	Initiated	Barrington Research	Outperform
Dec-01-11	Reiterated	Ladenburg Thalmann	Buy
Jul-14-11	Initiated	Ladenburg Thalmann	Buy

View All

Opko Health Inc Stock (OPK) Latest News

May 01, 2026

HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat

May 01, 2026

OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill

May 01, 2026

OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com

May 01, 2026

Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa

Apr 30, 2026

OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider

Apr 30, 2026

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com

Apr 30, 2026

Kidney drug RAYALDEE targets China as OPKO takes 15% Nicoya stake - Stock Titan

Apr 30, 2026

Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat

Apr 30, 2026

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - Yahoo Finance

Apr 30, 2026

Apr 29, 2026

OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN

Apr 29, 2026

OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com

Apr 29, 2026

OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo

Apr 29, 2026

OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat

Apr 29, 2026

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Apr 29, 2026

H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia

Apr 29, 2026

OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat

Apr 29, 2026

H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com

Apr 29, 2026

OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga

Apr 29, 2026